PacBio announced a new partnership with Basecamp Research, a leading AI laboratory, to supply 100,000 deeply sequenced metagenomic samples for the Trillion Gene Atlas initiative. The collaboration will generate high‑fidelity data from more than 31 countries across five continents, creating the largest and most diverse HiFi metagenomic dataset to date.
The Trillion Gene Atlas aims to expand known evolutionary genetic diversity by 100‑fold by collecting genomic data from over 100 million species across thousands of sites worldwide. Basecamp’s EDEN model will use the data to train biological foundation models, with the project set to compress decades of data gathering into less than two years.
PacBio will use its Revio system with SPRQ‑Nx chemistry to deliver HiFi reads that exceed 99% accuracy and long read lengths, enabling complete, strain‑resolved assemblies and accurate reconstruction of repeats, mobile elements, plasmids, phages, and operons. The chemistry is expected to keep sequencing costs below $300 per human genome at scale, supporting the project’s economic viability.
Christian Henry, President and CEO of PacBio, said, "PacBio HiFi sequencing delivers highly accurate long reads that preserve full genomic context and enables subspecies and even strain‑level resolution in complex samples. HiFi data provides the reliable, information‑rich foundation biological AI models need to learn from nature at scale and power initiatives like the Trillion Gene Atlas." He added, "Significantly lower costs enabled by SPRQ‑Nx will catalyze our next phase of growth in 2026 and beyond."
The contract expands PacBio’s presence in the rapidly growing metagenomics and AI‑driven biology markets, reinforcing its strategy to position HiFi sequencing as the preferred platform for high‑quality, large‑scale genomic data. PacBio’s recent Q4 2025 results showed revenue of $44.6 million, a 14% year‑over‑year increase, and a non‑GAAP gross margin of 40%, up from 31% in the prior year. Full‑year 2025 revenue reached $160 million, a modest 4% rise, while the company’s net loss narrowed to $37.6 million from $55.3 million in 2024.
The announcement was well received by investors, reflecting confidence in PacBio’s long‑read technology and its expanding role in AI‑driven biology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.